Chronic myeloid leukemia market 2022

80 %
20 %
Information about Chronic myeloid leukemia market 2022
Business & Mgmt

Published on February 26, 2014

Author: NancyFreedman

Source: slideshare.net

Description

Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients’ survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems

PharmaPoint: Chronic Myeloid Leukemia (CML) – Global Drug Forecast and Market Analysis to 2022 by GlobalData Explore all reports for “Cancer Drugs” market @ http://www.rnrmarketresearch.com/reports/lifesciences/pharmaceuticals/diseases-treatment/cancer-drugs . © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441

PharmaPoint: Chronic Myeloid Leukemia (CML) – Global Drug Forecast and Market Analysis to 2022 Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients’ survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems Request sample copy of this report @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=150295 . © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441

PharmaPoint: Chronic Myeloid Leukemia (CML) – Global Drug Forecast and Market Analysis to 2022 Key Questions Answered •How will the CML market size and composition change over the forecast period? •How will the TKIs be used differently in lines of therapy and in different patient segments? •The unmet needs of many CML patients are relatively low. What remaining needs exist, and what qualities must potential new market entrants have to compete in this space? •Will the entry of generic imatinib influence physician prescribing patterns? Why or why not? •What are the strengths and weaknesses of Gleevec, Tasigna, Sprycel, Bosulif, Iclusig and Synribo, and how do they stack up against one another? Which will have the greatest commercial success over the forecast period? •Do key opinion leaders believe that discontinuation of TKI therapy is feasible? For which patients? Complete report available @ http://www.rnrmarketresearch.com/pharmapoint-chronic-myeloidleukemia-cml-global-drug-forecast-and-market-analysis-to-2022-marketreport.html . © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441

PharmaPoint: Chronic Myeloid Leukemia (CML) – Global Drug Forecast and Market Analysis to 2022 Scope •Overview of CML, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines. •Annualized CML therapeutics market revenue, annual cost of therapy and treatment usage pattern data by patient segment forecast from 2012 to 2022. •Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the CML therapeutics market •Pipeline analysis: The CML pipeline is exceptionally weak, due to the relatively low level of unmet need. Innovative early-stage projects are highlighted, supplemented with KOL opinions about the validity of new targets. •Analysis of the current and future market competition in the global CML market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. Request sample copy of this report @ © RnRMarketResearch.com ; http://www.rnrmarketresearch.com/contacts/request-sample?rname=150295 . sales@rnrmarketresearch.com ; +1 888 391 5441

PharmaPoint: Chronic Myeloid Leukemia (CML) – Global Drug Forecast and Market Analysis to 2022 Reasons to buy •Develop business strategies by understanding the trends shaping and driving the global CML therapeutics market. •Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global CML therapeutics market in future. •Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. •Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. •Forecast drug sales in the global CML therapeutics market from 2012-2022. •Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. Request sample copy of this report @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=150295 . © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441

PharmaPoint: Chronic Myeloid Leukemia (CML) – Global Drug Forecast and Market Analysis to 2022 For more details contact Mr. Priyank Tiwari: sales@rnrmarketresearch.com / +18883915441 RnR Market Research RnRMarketResearch.com, an online repository of market research reports, offers in-depth analysis of over 5000 market segments. RnR Market Research library has syndicated reports by leading market research publishers across the globe. © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441

Add a comment

Related presentations

Related pages

Chronic Myeloid Leukemia Market 2022 - YouTube

Complete report is available @ http://www.rnrmarketresearch.com/phar... . Chronic myeloid leukemia (CML) is a rare myeloproliferative blood ...
Read more

Synribo (Chronic Myeloid Leukemia) - Forecast and Market ...

Description: Synribo (Chronic Myeloid Leukemia) ... Forecast and Market Analysis to 2022”. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood
Read more

Research and Markets: Gleevec (Chronic Myeloid Leukemia ...

... (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022 ... Forecast and Market Analysis to 2022. Chronic myeloid leukemia (CML) ...
Read more

Research and Markets: Synribo (Chronic Myeloid Leukemia ...

Research and Markets: Synribo (Chronic Myeloid Leukemia) ... Forecast and Market Analysis to 2022. Chronic myeloid leukemia (CML) ...
Read more

Marktanalyse - Bosulif (Chronic Myeloid Leukemia ...

Marktanalyse - Bosulif (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022 GlobalData 05.2013 54 Seiten Typ: Marktanalyse Verfüg ...
Read more

Gleevec (Chronic Myeloid Leukemia) - Forecast and Market ...

[53 Pages Report] Check for Discount on Gleevec (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022 report by GlobalData. GlobalData has ...
Read more